Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Outpatients | 1 | 2020 | 3417 | 0.33 | Why? |
| Saliva | 1 | 2020 | 4679 | 0.26 | Why? |
| Lymphoma, AIDS-Related | 1 | 2018 | 13 | 0.19 | Why? |
| Hodgkin Disease | 1 | 2018 | 204 | 0.14 | Why? |
| Herpesvirus 4, Human | 1 | 2018 | 387 | 0.14 | Why? |
| Nursing Homes | 2 | 2020 | 4155 | 0.12 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.11 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.11 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.10 | Why? |
| Immunity, Humoral | 2 | 2021 | 4849 | 0.10 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| United Kingdom | 4 | 2021 | 18046 | 0.09 | Why? |
| Autoimmune Diseases | 1 | 2021 | 1996 | 0.09 | Why? |
| DNA, Viral | 1 | 2018 | 2521 | 0.08 | Why? |
| Sensitivity and Specificity | 4 | 2020 | 22971 | 0.08 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.08 | Why? |
| T-Lymphocytes | 2 | 2021 | 6670 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.08 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.07 | Why? |
| Occupational Diseases | 1 | 2020 | 2787 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Kidney Failure, Chronic | 1 | 2021 | 3222 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| London | 2 | 2021 | 2166 | 0.07 | Why? |
| Renal Dialysis | 1 | 2021 | 4358 | 0.07 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Genes, Essential | 1 | 2021 | 34 | 0.06 | Why? |
| Ribonuclease P | 1 | 2021 | 84 | 0.06 | Why? |
| Gene Dosage | 1 | 2021 | 101 | 0.06 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.05 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.05 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2021 | 325 | 0.05 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.04 | Why? |
| Biological Assay | 1 | 2020 | 367 | 0.04 | Why? |
| Reference Standards | 1 | 2021 | 1163 | 0.04 | Why? |
| In Situ Hybridization | 1 | 2018 | 390 | 0.04 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.04 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.04 | Why? |
| Humans | 16 | 2021 | 930598 | 0.03 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Male | 7 | 2021 | 367725 | 0.03 | Why? |
| Adult | 5 | 2021 | 244371 | 0.03 | Why? |
| Female | 7 | 2021 | 380317 | 0.03 | Why? |
| HIV Infections | 1 | 2018 | 11620 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.03 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.03 | Why? |
| CRISPR-Cas Systems | 1 | 2020 | 1397 | 0.03 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Immunity | 1 | 2021 | 2651 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2021 | 3614 | 0.02 | Why? |
| Serologic Tests | 1 | 2021 | 4359 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2020 | 3388 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2021 | 6740 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 7868 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.02 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.02 | Why? |
| Aged | 4 | 2021 | 215776 | 0.02 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Immunosuppressive Agents | 1 | 2021 | 6331 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 13720 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
Randell's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(78)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(149)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_